Mast cells and mastocytosis:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Philadelphia, PA [u.a.]
Saunders
2006
|
| Schriftenreihe: | Immunology and allergy clinics of North America
26,3 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XV S., S. 387 - 601 Ill., graph. Darst. |
| ISBN: | 1416038086 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV021772218 | ||
| 003 | DE-604 | ||
| 005 | 20061107 | ||
| 007 | t | ||
| 008 | 061018s2006 ad|| |||| 00||| eng d | ||
| 020 | |a 1416038086 |9 1-4160-3808-6 | ||
| 035 | |a (OCoLC)73174499 | ||
| 035 | |a (DE-599)BVBBV021772218 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-29 |a DE-355 | ||
| 050 | 0 | |a RC583 | |
| 084 | |a XD 2800 |0 (DE-625)152549:12905 |2 rvk | ||
| 245 | 1 | 0 | |a Mast cells and mastocytosis |c guest ed. Cem Akin |
| 264 | 1 | |a Philadelphia, PA [u.a.] |b Saunders |c 2006 | |
| 300 | |a XV S., S. 387 - 601 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Immunology and allergy clinics of North America |v 26,3 | |
| 650 | 4 | |a Mast Cells |x physiology | |
| 650 | 4 | |a Mast cell disease | |
| 650 | 4 | |a Mast cells | |
| 650 | 4 | |a Mastocytosis | |
| 650 | 0 | 7 | |a Mastzelle |0 (DE-588)4194827-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Mastozytose |0 (DE-588)4210045-8 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Mastzelle |0 (DE-588)4194827-0 |D s |
| 689 | 0 | 1 | |a Mastozytose |0 (DE-588)4210045-8 |D s |
| 689 | 0 | |C b |5 DE-604 | |
| 700 | 1 | |a Akin, Cem |e Sonstige |4 oth | |
| 830 | 0 | |a Immunology and allergy clinics of North America |v 26,3 |w (DE-604)BV000645505 |9 26,3 | |
| 856 | 4 | 2 | |m Digitalisierung UB Regensburg |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014985133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-014985133 | ||
Datensatz im Suchindex
| _version_ | 1804135640589139968 |
|---|---|
| adam_text | MAST CELLS AND MASTOCYTOSK
CONTENTS
Foreword
Rafeul Alam
Preface
Cem Akin
Molecular Mechanisms of Mast Cell Development
Yukihiko Kitamura, Keisuke Oboki, and Akihiko
Mast cells are progeny of multipotential hematopoietic stem cells
(MHSCs). MHSCs commit to the mast cell lineage in the bone mar¬
row, and the mast cell—committed progenitors leave the bone mar¬
row, migrate in blood, invade connective or mucosal tissue, and
then proliferate and differentiate to connective tissue-type or muco¬
sal mast cells. GATA-1, GATA-2, and PU.l transcription factors
seem to be involved in the commitment to mast cells, and MITF,
a basic helix-loop-helix leucine zipper-type transcription factor,
seems to be involved in the migration, phenotypic expression,
and survival of mast cells. KIT ligand (KITL) is the most important
cytokine
KITL. Tissues of loss-of-function mutants of KIT, KITL, or MITF
are deficient in mast cells.
Mast Cells: Not Only in Allergy
Ido
Mast cells are classically known as the central effector cells in aller¬
gic reactions. In the past decade, however, new evidence emerged
that assigned them roles in settings extending beyond their classic
context, such as innate immunity, autoimmunity, chronic inflam¬
mation, and atherosclerosis.
VOLUME
Adaptive and Innate Immune Reactions Regulating Mast Cell
Activation: from Receptor-mediated Signaling to Responses
Christine Tkaczyk,
Alasdair M. Gilfillan
Mast cells play a role in the body s defense mechanisms associated
with innate and adaptive immune reactions. When activated by
such reactions, mast cells secrete a diverse group of inflammatory
mediators whose role is to help the body destroy or clear parasites,
bacteria, and viruses. It is the same mediators produced by these
defense mechanisms, however, that are responsible for the adverse
inflammatory cellular reactions that are manifested in allergic dis¬
ease states such as asthma. A better understanding of the mechan¬
isms by which these
activation may provide insight into how these detrimental aspects
of mast cell activation may be isolated from the beneficial aspects.
Thus, in this article, we discuss the current understanding about
how innate and adaptive immune responses lead to the release
of inflammatory mediators from mast cells and discuss the intracel-
lular signaling mechanisms that regulate these responses.
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Lawrence B. Schwartz
Serum (or plasma) levels of total and mature tryptase measure¬
ments are useful in the diagnostic evaluation of systemic anaphy¬
laxis and systemic mastocytosis, but must be interpreted in the
context of a complete workup.
Mast Cell Mediators in Allergic Inflammation
and Mastocytosis
Mariana Castells
Mast cells possess an array of potent inflammatory mediators that
induce acute symptoms, such as urticaria, angioedema, broncho-
constriction, diarrhea, vomiting, hypotension and cardiovascular
collapse, which can result in death. In contrast, mast cell mediators
can be beneficial in the setting of acute infections, cardiovascular
diseases, and cancer. The balance between the detrimental and ben¬
eficial roles of mast cells and their mediators is not completely un¬
derstood. Although the symptoms of acute mediator release can be
reversed with epinephrine and mediator
release of
cytokines, and chemokines can lead to chronic and debilitating
symptoms in patients with mastocytosis. Identification of the mole¬
cular factors and mechanisms that control the release of mast cell
mediators will benefit all patients with mast cell activation syn¬
dromes and mastocytosis.
CONTENTS
Systemie Mastocytosis:
and Differential Diagnosis
Joseph H. Butterfield
Systemic mastocytosis remains a diagnostic challenge because of its
rarity and because many of its symptoms also occur in more com¬
mon disorders. Urticaria
as a visible marker of mast cell proliferation. When skin lesions
are overlooked or absent or patients with SM present with nonspe¬
cific findings of organ dysfunction, the diagnosis can be greatly
delayed. Improved diagnosis continues to depend on clinical
suspicion, appropriate biopsy, and mediator quantitation.
Diagnostic Evaluation and Classification of Mastocytosis
Peter
Mastocytosis is a term collectively used for a group of disorders
characterized by abnormal accumulation of mast cells (MCs) in
one or more organ systems. Cutaneous mastocytosis is a benign
disease of the skin that usually manifests in early childhood and of¬
ten regresses spontaneously before or during puberty. By contrast,
systemic mastocytosis (SM) is a persistent disease of neoplastic
MCs. In these patients,
visceral organs with or without skin involvement. In most patients
with SM, the somatic KIT mutation D816V is detectable. The clin¬
ical course in SM is variable, ranging from an asymptomatic status
for many years with a normal life expectancy to highly aggressive
cases with a poor prognosis and short survival. The World Health
Organization classification defines five categories of SM: indolent
SM, aggressive SM, SM with associated clonal
MC lineage disease, and mast cell leukemia. This article provides
a summary of current markers, criteria, and tests used to diagnose
mastocytosis and to discriminate between
disease.
Flow Cytometric Analysis of Normal and Neoplastic
Mast Cells: Role in Diagnosis and Follow-Up of Mast
Cell Disease
Luis Escribano,
and Alberto Orfao, on behalf of the Red
de Mastodtosis
Human mast cells (MCs) are directly derived from human pluripo-
tent CD34+ stem and progenitor hematopoietic cells, with stem cell
factor being a critical growth factor supporting human
eration, differentiation, and survival. Because of the advantages
that flow cytometry offers (it allows rapid, objective, and sensitive
multiparameter analysis of high numbers of cells from a sample,
CONTENTS
with information being provided on the basis of a single cell), it has
become the method of choice in the past decade for immunopheno-
typic identification, enumeration, and characterization of human
MCs in bone marrow and other tissue specimens.
Treatment of Systemic Mastocytosis
Todd M. Wilson, Dean D. Metcalfe, and Jamie Robyn
Systemic mastocytosis is a heterogeneous disorder characterized by
diverse signs and symptoms. No curative therapy presently exists.
Conventional management has relied on agents that antagonize
mediators released by mast cells, inhibit mediator secretion, or
modulate mast cell proliferation. Recent advances in our molecular
understanding of the pathophysiology of systemic mastocytosis
have provided new therapeutic considerations. Conventional man¬
agement and promising novel agents are summarized in this
review.
КГГ
as Therapeutic Targets
Jason Gotlib
In most cases, systemic mastocytosis (SM) is pathogenetically
linked to constitutive activation of the KIT receptor tyrosine kinase
(TK). At the beginning of the targeted therapy revolution, the effi¬
cacy of imatinib in gastrointestinal stromal tumors heralded enthu¬
siasm regarding the utility of TK inhibition as a treatment strategy
for other KIT-driven diseases, such as SM. However, the initial exu¬
berance about the specific translatability of imatinib to mast cell
disorders has been tempered by in vitro and in vivo imatinib resis¬
tance of the most common SM-related mutation, D816V KIT. Struc¬
turally different TK inhibitors with nanomolar inhibitory activity
against D816V KIT are currently in the preclinical and early clinical
phases of testing, including PKC412, dasatinib (BMS-354825), and
AP23464. This review highlights TK inhibition of KIT as a thera¬
peutic approach in SM and other molecularly targeted approaches
against neoplastic mast cells.
Index
CONTENTS
|
| adam_txt |
MAST CELLS AND MASTOCYTOSK
CONTENTS
Foreword
Rafeul Alam
Preface
Cem Akin
Molecular Mechanisms of Mast Cell Development
Yukihiko Kitamura, Keisuke Oboki, and Akihiko
Mast cells are progeny of multipotential hematopoietic stem cells
(MHSCs). MHSCs commit to the mast cell lineage in the bone mar¬
row, and the mast cell—committed progenitors leave the bone mar¬
row, migrate in blood, invade connective or mucosal tissue, and
then proliferate and differentiate to connective tissue-type or muco¬
sal mast cells. GATA-1, GATA-2, and PU.l transcription factors
seem to be involved in the commitment to mast cells, and MITF,
a basic helix-loop-helix leucine zipper-type transcription factor,
seems to be involved in the migration, phenotypic expression,
and survival of mast cells. KIT ligand (KITL) is the most important
cytokine
KITL. Tissues of loss-of-function mutants of KIT, KITL, or MITF
are deficient in mast cells.
Mast Cells: Not Only in Allergy
Ido
Mast cells are classically known as the central effector cells in aller¬
gic reactions. In the past decade, however, new evidence emerged
that assigned them roles in settings extending beyond their classic
context, such as innate immunity, autoimmunity, chronic inflam¬
mation, and atherosclerosis.
VOLUME
Adaptive and Innate Immune Reactions Regulating Mast Cell
Activation: from Receptor-mediated Signaling to Responses
Christine Tkaczyk,
Alasdair M. Gilfillan
Mast cells play a role in the body's defense mechanisms associated
with innate and adaptive immune reactions. When activated by
such reactions, mast cells secrete a diverse group of inflammatory
mediators whose role is to help the body destroy or clear parasites,
bacteria, and viruses. It is the same mediators produced by these
defense mechanisms, however, that are responsible for the adverse
inflammatory cellular reactions that are manifested in allergic dis¬
ease states such as asthma. A better understanding of the mechan¬
isms by which these
activation may provide insight into how these detrimental aspects
of mast cell activation may be isolated from the beneficial aspects.
Thus, in this article, we discuss the current understanding about
how innate and adaptive immune responses lead to the release
of inflammatory mediators from mast cells and discuss the intracel-
lular signaling mechanisms that regulate these responses.
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Lawrence B. Schwartz
Serum (or plasma) levels of total and mature tryptase measure¬
ments are useful in the diagnostic evaluation of systemic anaphy¬
laxis and systemic mastocytosis, but must be interpreted in the
context of a complete workup.
Mast Cell Mediators in Allergic Inflammation
and Mastocytosis
Mariana Castells
Mast cells possess an array of potent inflammatory mediators that
induce acute symptoms, such as urticaria, angioedema, broncho-
constriction, diarrhea, vomiting, hypotension and cardiovascular
collapse, which can result in death. In contrast, mast cell mediators
can be beneficial in the setting of acute infections, cardiovascular
diseases, and cancer. The balance between the detrimental and ben¬
eficial roles of mast cells and their mediators is not completely un¬
derstood. Although the symptoms of acute mediator release can be
reversed with epinephrine and mediator
release of
cytokines, and chemokines can lead to chronic and debilitating
symptoms in patients with mastocytosis. Identification of the mole¬
cular factors and mechanisms that control the release of mast cell
mediators will benefit all patients with mast cell activation syn¬
dromes and mastocytosis.
CONTENTS
Systemie Mastocytosis:
and Differential Diagnosis
Joseph H. Butterfield
Systemic mastocytosis remains a diagnostic challenge because of its
rarity and because many of its symptoms also occur in more com¬
mon disorders. Urticaria
as a visible marker of mast cell proliferation. When skin lesions
are overlooked or absent or patients with SM present with nonspe¬
cific findings of organ dysfunction, the diagnosis can be greatly
delayed. Improved diagnosis continues to depend on clinical
suspicion, appropriate biopsy, and mediator quantitation.
Diagnostic Evaluation and Classification of Mastocytosis
Peter
Mastocytosis is a term collectively used for a group of disorders
characterized by abnormal accumulation of mast cells (MCs) in
one or more organ systems. Cutaneous mastocytosis is a benign
disease of the skin that usually manifests in early childhood and of¬
ten regresses spontaneously before or during puberty. By contrast,
systemic mastocytosis (SM) is a persistent disease of neoplastic
MCs. In these patients,
visceral organs with or without skin involvement. In most patients
with SM, the somatic KIT mutation D816V is detectable. The clin¬
ical course in SM is variable, ranging from an asymptomatic status
for many years with a normal life expectancy to highly aggressive
cases with a poor prognosis and short survival. The World Health
Organization classification defines five categories of SM: indolent
SM, aggressive SM, SM with associated clonal
MC lineage disease, and mast cell leukemia. This article provides
a summary of current markers, criteria, and tests used to diagnose
mastocytosis and to discriminate between
disease.
Flow Cytometric Analysis of Normal and Neoplastic
Mast Cells: Role in Diagnosis and Follow-Up of Mast
Cell Disease
Luis Escribano,
and Alberto Orfao, on behalf of the Red
de Mastodtosis
Human mast cells (MCs) are directly derived from human pluripo-
tent CD34+ stem and progenitor hematopoietic cells, with stem cell
factor being a critical growth factor supporting human
eration, differentiation, and survival. Because of the advantages
that flow cytometry offers (it allows rapid, objective, and sensitive
multiparameter analysis of high numbers of cells from a sample,
CONTENTS
with information being provided on the basis of a single cell), it has
become the method of choice in the past decade for immunopheno-
typic identification, enumeration, and characterization of human
MCs in bone marrow and other tissue specimens.
Treatment of Systemic Mastocytosis
Todd M. Wilson, Dean D. Metcalfe, and Jamie Robyn
Systemic mastocytosis is a heterogeneous disorder characterized by
diverse signs and symptoms. No curative therapy presently exists.
Conventional management has relied on agents that antagonize
mediators released by mast cells, inhibit mediator secretion, or
modulate mast cell proliferation. Recent advances in our molecular
understanding of the pathophysiology of systemic mastocytosis
have provided new therapeutic considerations. Conventional man¬
agement and promising novel agents are summarized in this
review.
КГГ
as Therapeutic Targets
Jason Gotlib
In most cases, systemic mastocytosis (SM) is pathogenetically
linked to constitutive activation of the KIT receptor tyrosine kinase
(TK). At the beginning of the targeted therapy revolution, the effi¬
cacy of imatinib in gastrointestinal stromal tumors heralded enthu¬
siasm regarding the utility of TK inhibition as a treatment strategy
for other KIT-driven diseases, such as SM. However, the initial exu¬
berance about the specific translatability of imatinib to mast cell
disorders has been tempered by in vitro and in vivo imatinib resis¬
tance of the most common SM-related mutation, D816V KIT. Struc¬
turally different TK inhibitors with nanomolar inhibitory activity
against D816V KIT are currently in the preclinical and early clinical
phases of testing, including PKC412, dasatinib (BMS-354825), and
AP23464. This review highlights TK inhibition of KIT as a thera¬
peutic approach in SM and other molecularly targeted approaches
against neoplastic mast cells.
Index
CONTENTS |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| building | Verbundindex |
| bvnumber | BV021772218 |
| callnumber-first | R - Medicine |
| callnumber-label | RC583 |
| callnumber-raw | RC583 |
| callnumber-search | RC583 |
| callnumber-sort | RC 3583 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XD 2800 |
| ctrlnum | (OCoLC)73174499 (DE-599)BVBBV021772218 |
| discipline | Medizin |
| discipline_str_mv | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01660nam a2200433 cb4500</leader><controlfield tag="001">BV021772218</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20061107 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">061018s2006 ad|| |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1416038086</subfield><subfield code="9">1-4160-3808-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)73174499</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV021772218</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC583</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XD 2800</subfield><subfield code="0">(DE-625)152549:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Mast cells and mastocytosis</subfield><subfield code="c">guest ed. Cem Akin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Philadelphia, PA [u.a.]</subfield><subfield code="b">Saunders</subfield><subfield code="c">2006</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XV S., S. 387 - 601</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">26,3</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mast Cells</subfield><subfield code="x">physiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mast cell disease</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mast cells</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Mastocytosis</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Mastzelle</subfield><subfield code="0">(DE-588)4194827-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Mastozytose</subfield><subfield code="0">(DE-588)4210045-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Mastzelle</subfield><subfield code="0">(DE-588)4194827-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Mastozytose</subfield><subfield code="0">(DE-588)4210045-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Akin, Cem</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Immunology and allergy clinics of North America</subfield><subfield code="v">26,3</subfield><subfield code="w">(DE-604)BV000645505</subfield><subfield code="9">26,3</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014985133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-014985133</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV021772218 |
| illustrated | Illustrated |
| index_date | 2024-07-02T15:38:51Z |
| indexdate | 2024-07-09T20:43:43Z |
| institution | BVB |
| isbn | 1416038086 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-014985133 |
| oclc_num | 73174499 |
| open_access_boolean | |
| owner | DE-29 DE-355 DE-BY-UBR |
| owner_facet | DE-29 DE-355 DE-BY-UBR |
| physical | XV S., S. 387 - 601 Ill., graph. Darst. |
| publishDate | 2006 |
| publishDateSearch | 2006 |
| publishDateSort | 2006 |
| publisher | Saunders |
| record_format | marc |
| series | Immunology and allergy clinics of North America |
| series2 | Immunology and allergy clinics of North America |
| spelling | Mast cells and mastocytosis guest ed. Cem Akin Philadelphia, PA [u.a.] Saunders 2006 XV S., S. 387 - 601 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Immunology and allergy clinics of North America 26,3 Mast Cells physiology Mast cell disease Mast cells Mastocytosis Mastzelle (DE-588)4194827-0 gnd rswk-swf Mastozytose (DE-588)4210045-8 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Mastzelle (DE-588)4194827-0 s Mastozytose (DE-588)4210045-8 s b DE-604 Akin, Cem Sonstige oth Immunology and allergy clinics of North America 26,3 (DE-604)BV000645505 26,3 Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014985133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Mast cells and mastocytosis Immunology and allergy clinics of North America Mast Cells physiology Mast cell disease Mast cells Mastocytosis Mastzelle (DE-588)4194827-0 gnd Mastozytose (DE-588)4210045-8 gnd |
| subject_GND | (DE-588)4194827-0 (DE-588)4210045-8 (DE-588)4143413-4 |
| title | Mast cells and mastocytosis |
| title_auth | Mast cells and mastocytosis |
| title_exact_search | Mast cells and mastocytosis |
| title_exact_search_txtP | Mast cells and mastocytosis |
| title_full | Mast cells and mastocytosis guest ed. Cem Akin |
| title_fullStr | Mast cells and mastocytosis guest ed. Cem Akin |
| title_full_unstemmed | Mast cells and mastocytosis guest ed. Cem Akin |
| title_short | Mast cells and mastocytosis |
| title_sort | mast cells and mastocytosis |
| topic | Mast Cells physiology Mast cell disease Mast cells Mastocytosis Mastzelle (DE-588)4194827-0 gnd Mastozytose (DE-588)4210045-8 gnd |
| topic_facet | Mast Cells physiology Mast cell disease Mast cells Mastocytosis Mastzelle Mastozytose Aufsatzsammlung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=014985133&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000645505 |
| work_keys_str_mv | AT akincem mastcellsandmastocytosis |